T Scientific KRX:057680KOSDAQ
티사이언티픽 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, T Scientific reported revenue of ₩7.0bn, down 15.0% year on year, and an operating loss of ₩536m. T Scientific (티사이언티픽) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Supply contract Swung to loss Screener
T Scientific quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩7.0bn | -15.0% | −₩536m margin −7.6% | −₩677m |
| Q1 2026 | ₩6.2bn | -12.4% | −₩1.0bn margin −16.9% | −₩1.0bn |
| Q4 2025 derived | ₩12.8bn | -20.6% | ₩1.2bn margin 9.1% | ₩254m |
| Q3 2025 | ₩8.5bn | -2.9% | −₩51m margin −0.6% | ₩95m |
| Q2 2025 | ₩8.3bn | -7.6% | ₩40m margin 0.5% | ₩1.6bn |
| Q1 2025 | ₩7.0bn | -23.7% | −₩888m margin −12.6% | −₩3.5bn |
| Q4 2024 derived | ₩16.1bn | +50.8% | −₩8.6bn margin −53.1% | ₩1.7bn |
| Q3 2024 | ₩8.7bn | +45.7% | −₩845m margin −9.7% | −₩4.4bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
T Scientific top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.